Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.
He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Latest From Andrew McConaghie
The UK biotech is set for a NASDAQ launch which could propel it to its first commercial launch by 2022.
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.
If J&J’s gamble on a single dose pays off, it could rapidly advance the fight against SARS-CoV2 – but a second study will provide a safety net.
After years of setbacks, Novavax is on the cusp of success with its COVID-19 vaccine - but a rapid scale up of manufacturing and commercial operations will be a huge challenge.
Companies will raise their COVID-19 vaccine prices once the pandemic is over – but key long-term data will determine which comes out on top.
Announcing its first big pharma deal, the Oxford-based biotech says there could be more to come – with mRNA pioneers also interested in shining a light on hidden drug targets.